title: Impact of withdrawing antithrombin III administration from management of septic patients with or without disseminated intravascular coagulation.
abstract: Antithrombin III (ATIII) of low doses (1500-3000 units per day for 3-5 days) has been used for treatment of disseminated intravascular coagulation (DIC) for decades in Japan. In this study, we have examined the impact of ATIII practice change on outcome in critically ill patients with sepsis and DIC. From April 2005 to September 2008, all septic patients admitted to our ICU were divided into two groups: before withdrawing ATIII (period 1) and after withdrawing ATIII (period 2). Patients treated with ATIII in the period 1 and those not treated with ATIII in the period 2 were then matched according to the similar Acute Physiology and Chronic Health Evaluation II scores (± 3) and the same diagnosis grouping. Sensitivity analysis was also conducted for patients with DIC. Forty-one out of 98 patients (41.8%) in the period 1 and only one out of 80 patients (1.3%) in the period 2 were treated with ATIII. Thirty pairs of the patients were matched. There was no difference between the two groups regarding the platelet counts and Sepsis-related Organ Failure Assessment scores at day 1 and day 4. A subgroup analysis was conducted with 12 patients diagnosed with DIC out of the 30 pairs. There was no difference between the two DIC groups for platelet counts, Sepsis-related organ failure assessment scores and DIC score at day 1 and also day 4. Although not significant, hospital mortality tended lower in the period 2. This study found that withdrawing ATIII administration from management of septic patients with or without DIC did not influence outcome.
authors.affiliation: Intensive Care Unit, Department of Anesthesiology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Kawano
authors.forename: Shigehiko
authors.initials: S
authors.lastname: Uchino
authors.forename: Arata
authors.initials: A
authors.lastname: Endo
authors.forename: Keita
authors.initials: K
authors.lastname: Saito
authors.forename: Kenichi
authors.initials: K
authors.lastname: Iwai
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kase
authors.forename: Masanori
authors.initials: M
authors.lastname: Takinami
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000990:Antithrombin III / Q000008:administration & dosage*; D016638:Critical Illness; D019468:Disease Management; D004211:Disseminated Intravascular Coagulation / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D012189:Retrospective Studies; D018805:Sepsis / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000990:Antithrombin III